Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer

Vascular disrupting agents (VDAs) represent a relatively distinct class of agents that target established blood vessels in tumors. In this study, we examined the preclinical activity of the second-generation VDA OXi4503 against human head and neck squamous cell carcinoma (HNSCC). Studies were perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Bothwell, Katelyn D., Folaron, Margaret, Seshadri, Mukund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728458/
https://www.ncbi.nlm.nih.gov/pubmed/26751478
http://dx.doi.org/10.3390/cancers8010011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728458/
https://www.ncbi.nlm.nih.gov/pubmed/26751478
http://dx.doi.org/10.3390/cancers8010011

Ejemplares similares